First Trimester Screening ( FTS )
LifeCell Diagnostics provides early detection screening methodologies for Down’s Syndrome (Trisomy 21), Edwards’ Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13) and Pre- Eclampsia with highest accuracy and confidence.To ensure a healthy baby, early detection and screening for abnormalities are necessary. The First Trimester Screening involves:
- The blood test is performed between 10-13 weeks and 6 days of pregnancy (first trimester) and evaluates for Chromosomal Abnormalities and Pre-Eclampsia.
- An ultrasound test to measure the amount of fluid behind baby’s neck (Nuchal Translucency).
Dual Marker/Combined test
Dual marker screening test assesses the possibility of Down’s syndrome (trisomy 21) and Edward’s syndrome (trisomy 18) in the fetus by analysing the biochemical levels of Free Beta HCG (human chorionic gonadotropin) and PAPP-A (Pregnancy Associated Plasma Protein) in maternal blood.
Combined Screening involves a combination of biochemical markers with biophysical markers (Nuchal Translucency & Nasal Bone) in the first trimester. Combined screening further offers high detection rate for chromosomal abnormalities. It is usually performed after 8 weeks of pregnancy up to 14 weeks.
|Markers||Free hCGβ + PAPP-A + NT + NB + FHR|
|Time of test ( in weeks)||11-13+6 weeks|
|Detection rate ( % )||95 %|
|False positive rate ( % )||3 %|
( Reference - S. Shiefa et al., First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free β-HCG for Down Syndrome, Patau Syndrome and Edward Syndrome; Indian J Clin Biochem. 2013 Jan; 28(1): 3–12.)